Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnosis and Therapy of RCC With 68Ga-PSMA and 177Lu-EB-PSMA-617
NCT05170555Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label, single-arm trial of 177Lu-EB-PSMA-617 in renal cell carcinoma (RCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Diagnostic value at 1 year. Status: unknown.
02
Drugs
177Lu-EB-PSMA-617
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05170555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170555.